Mesenteric fibromatosis is a rare type of desmoid tumor characterized by local aggressiveness and a tendency to relapse. In view of these characteristics it may be considered a low-grade fibrosarcoma. Camurati-Engelmann disease is a very rare form of bone dysplasia characterized by osteosclerosis of the diaphyses of the long bones. Here we describe the case of a male patient affected by these two rare diseases in association with chronic inflammatory intestinal disease.
HeiskanenI., JarvinenH.J.: Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment.Int J Colorectal Dis, 11: 157–162, 1996.
2.
KnudsenA.L., BulowS.: Desmoid tumour in familial adenomatous polyposis. A review of literature.Fam Cancer, 1: 111–119, 2001.
RodriguezJ.A., GuardaL.A., RosaiJ.: Mesenteric fibromatosis with involvement of the gastrointestinal tract. A GIST simulator: a study of 25 cases.Am J Clin Pathol, 121: 93–98, 2004.
6.
JanssensK., Gershoni-BaruchR., GuanabensN., MigoneN., RalstonS., BonduelleM., LissensW., Van MaldergemL., VanhoenackerF., VerbruggenL., Van HulW.: Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease.Nat Genet, 26: 273–275, 2000.
MasseyH.M., ScopesJ., HortonM.A., FlanaganA.M.: Trasforming growth factor-beta 1 (TGF-beta) stimulates the osteoclast-forming potential of peripheral blood hematopoietic precursor in a lymphocyte-rich microenvironment.Bone, 28: 577–562, 2003.
9.
McGowanN.W., MacPhersonH., JanssensK., Van HulW., FrithJ.C., FraserW.D., RalstonS.H., HelfrichM.H.: A mutation affecting the latency-associated peptide of TGFbetal in Camurati-Engelmann disease enhances osteoclast formation in vitro.J Clin End Met, 88: 3321–3326, 2003.
BusP.J., VerspagetH.W., van KriekenJ.H., de RoosA., KeizerH.J., BemelmanW.A., VasenH.F., LamersC.B., GriffioenG.: Treatment of mesenteric desmoid tumors with anti-oestrogenic agent toremifene: case histories and an overview of the literature.Eur J Gastroenterol Hepatol, 11: 1179–1183, 1999.
18.
LinchH.T., FitzgibbonsR.Jr., ChongS.: Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome.Dis Colon Rectum, 37: 260–267, 1994.
19.
PoritzL.S., BlacksteinM., BerkT., GallingerS., McLeodR.S., CohenZ.: Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoid tumors.Dis Colon Rectum, 44: 1268–1273, 2001.
20.
AzzarelliA., GronchiA., BertulliR.: Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis.Cancer, 92: 1259–1264, 2001.
21.
HeidemannJ., OgawaH., OttersonM.F., ShidhamV.B., BinionD.G.: Antiangiogenic treatment of mesenteric desmoid tumors with toremifene and interferon alfa-2b: report of two cases.Dis Colon Rectum, 47: 118–122, 2004.
